Can investing in infectious disease pay off? Vir Biotechnology’s tightrope walk shows it’s a struggle; Ultragenyx reports early success with Angelman syndrome drug, backing up 2022 acquisition

Taking stock of the drug industry, from the lab to the medicine chest

April 15, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Mike Reddy for STAT STAT+ | Can investing in infectious disease pay off? Vir Biotechnology's tightrope walk shows it's a struggle In 2017, Vir's founders threw millions at infectious disease. Covid made them look like geniuses. The road since then has been far rockier. By Jason Mast STAT+ | Thanks to CVS, a biosimilar version of AbbVie's Humira is grabbing huge market share "CVS came up with another crafty vehicle to capture money before it goes out the door," said Chris Brown, who heads McAteer Consulting. By Ed Silverman STAT+ | Ultragenyx reports early success with Angelman syndrome drug, backing up 2022 acquisition The company's drug was generally safe and led to rapid and clinically meaningful improvements in cognition, communication, and sleep. By Allison DeAngelis Adobe Opinion: ADHD is often overlooked in girls and women. They need help, too It is harder for girls and women to access appropriate ADHD diagnosis and treatment, and shortages of medication further reduce access. By Michael Morse and Kathleen Nadeau

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser